From pathogenesis to precision medicine in systemic lupus erythematosus: Emerging biomarkers and targeted interventions Authors: Weiya Lan, Qianwei Lu, Zong Jiang, Wukai Ma, Lei Hou, Danyang Li, Xudong Rui, Fang Tang Published: 2026 ABSTRACT SummarySystemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by immune dysregulation, autoantibody production, and chronic inflammation, which can potentially damage almost any organ. The estimated worldwide prevalence of SLE ranges from 5 to 7 million, and it is associated with significant morbidity, premature death, and significant global disparities in terms of sex, ethnicity/race, and geography. The key pathological basis of SLE is autoantibody production and the subsequent immune complex-mediated tissue damage, which is the culmina+ abnormal type I interferon signaling, formation of neutrophil extracellular traps, activation of plasmacytoid dendritic cells, imbalance in the homeostasis of T cells and B cells, hyperactivation of B cells, and dysregulated germinal center responses. This review offers a summary of the immunological mechanisms of SLE, encompassing genetic predisposition, epigenetic alterations, and innate and adaptive immune features. In addition, organ-specific manifestations of SLE, including lupus nephritis, neuropsychiatric SLE, cutaneous disease, cardiovascular involvement, hematological involvement, and musculoskeletal sequelae have also been discussed in the context of immune dysregulation. Furthermore, the recent progress in SLE biomarkers, multi-omics integration, and machine learning techniques that allow for molecular stratification and precision medicine have been highlighted. Finally, standard of care treatments, approved biologics, and novel immunotherapies (e.g., CAR-T cell strategies and restoration of immune tolerance), as well as the unmet needs, have been summarized. Altogether, this review integrates the immunological mechanisms with clinical translation to propose a framework for personalized and potentially curative treatment of SLE. Introduction Systemic lupus erythematosus (SLE) is a chronic, multi-organ autoimmune disease that is driven by the loss of self-tolerance, autoantibody generation, and inflammation. Approximately 5–7 million people worldwide are affected by SLE, and its prevalence is increasing due to heightened diagnostic sensitivity, prolonged lifespan, and demographic changes.1,2 Global epidemiology and disease burden The prevalence of SLE differs across geographical areas and ranges from 20 to 150 cases per 100,000 individuals, depending on ethnicity and environmental factors.3 Furthermore, SLE is associated with significant morbidity, poor quality of life, complications such as premature cardiovascular mortality and end-stage renal disease (ESRD), and substantial economic burden.4 Global disparities: sex, race, and geography Epidemiological studies have revealed striking demographic differences in the prevalence of SLE. Almost 90% of the adult SLE cases are women of childbearing age, which is suggestive of hormonal influences on the T and B cell-mediated immune responses and tolerance pathways.5 In addition, higher prevalence, earlier onset, exacerbated organ involvement with aggressive forms of lupus nephritis (LN), and increased risk of death have been reported among individuals of African, Hispanic/Latino, Asian and Native American heritage.6 Geographically, SLE is most prevalent in North America, the Caribbean, and some parts of Latin America, while lower rates have been reported in Europe and sub-Saharan Africa.1,6 These differences underscore the role of genetic susceptibility, epigenetic regulation, environmental factors, and structural inequities in the cause and consequence of SLE.7,8 The immunological basis of SLE Despite its clinical diversity, the key pathological mechanism of SLE is immune dysregulation.7,8 Disruption in the central and peripheral tolerance mechanisms allows autoreactive B cells and T cells to expand, which is accompanied by dysregulated germinal center activity, abnormal interferon (IFN) signaling, formation of neutrophil extracellular traps (NETs), complement activation, and sustained inflammation.7,8,9 These immunological perturbations not only trigger the SLE pathogenesis, but also exacerbate flares, organ damage, and long-term complications.2,4,7 Therefore, the effective treatment and management of SLE hinges on the identification of the primary immune pathways driving the pathological changes in individual patients, and the development of personalized therapeutic strategies that precisely target these dysregulated pathways.10,11 Given the rapidly evolving field of SLE diagnosis and therapy, it is critical to monitor and review the latest data.7,8,9 Recent translational breakthroughs (2021–2025) There have been significant mechanistic and translational advances in the field of SLE over the last five years.7,8,9 For instance, single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and multi-omics integration have revolutionized the study of immune cell states, molecular signatures, and tissue-specific pathology.9,12,13 Based on these approaches, recent studies have proposed altered germinal center dynamics, IFN- and IL-21-induced B cell hyperactivation, and innate immune anomalies as the earliest triggers of SLE.8,13 Furthermore, high-dimensional profiling of immune cells has revealed molecular signatures associated with SLE progression and relapse, which can be useful in identifying novel diagnostic and prognostic biomarkers.9,14 Likewise, artificial intelligence (AI) and machine learning (ML) have refined the phenotyping of autoantibody trajectories, immune gene networks, and response predictors for therapeutic agents.11,15 Finally, various immunotherapeutic strategies have been devised for SLE, such as anti-type I IFNs, BAFF inhibitors, JAK/BTK inhibitors, regulatory T cells (Tregs), and the first-in-human CD19-specific chimeric antigen receptor (CAR)-T cells for refractory SLE.16,17,18,19,20 Scope and goals of this review This review summarizes current knowledge regarding the immunopathogenesis of SLE,7,8 including genetic and epigenetic factors, innate and adaptive responses,7,8,9 and organ-specific immunology.13,14,21 In addition, the established and emerging biomarkers of SLE,12,14,22,23 and the traditional, biological, and next-generation therapeutic approaches,10,17,19 have also been discussed. The review highlights the high-impact translational breakthroughs between 2021 and 2025,24,25 to provide the latest insights into personalized and potentially curative immunomodulatory strategies for SLE.16,19,26 Genetic and epigenetic underpinnings Genetic architecture of SLE The genetic landscape of SLE is extremely complex, and hundreds of susceptible loci have been identified among different ethnic groups. In addition, the hereditary aspect of SLE is supported by familial aggregation and higher concordance among monozygotic twins, and the estimated heritability ranges between 44% and 66%.27 Genome-wide association studies (GWAS), whole-genome sequencing (WGS), and multi-ancestry meta-analyses have identified multiple human leukocyte antigen (HLA) and non-HLA loci associated with SLE risk, allowing researchers to construct refined polygenic risk models and ancestry-specific genetic signatures.28 HLA associations in SLE The HLA region on chromosome 6 is the most significant susceptibility locus associated with SLE. Class II alleles such as HLA-DRB103:01, DRB115:01, DQA101:02, and DQA105:01 are strongly associated across European and Asian ancestry, as well as in African and Hispanic/Latino populations. These alleles contribute to epitope-presenting diversity and promote the activation of autoreactive CD4+ T cells and germinal centers.27 Structural analyses suggest that these HLA variants selectively display nucleic acid-based autoantigens, leading to the production of autoantibodies and amplification of type I IFN loops.29 Although the high levels of linkage disequilibrium and epistatic interactions within the HLA region limit mechanistic dissection, its fundamental role in the loss of tolerance in SLE is well-established. Non-HLA risk loci in SLE More than 180 non-HLA loci with SLE association have been discovered till date, and several are involved in innate immune sensing, B cell activation, and cytokine regulation. STAT4, a transcriptional factor activated by IL-12 and type I IFN signaling pathways, is one of the most robustly associated non-HLA SLE risk genes. For instance, the STAT4rs7574865 T allele correlates with increased susceptibility to SLE and related phenotypes such as LN and vascular complications.30 IRF5, a crucial IFN regulatory factor, promotes the secretion of type I IFNs through nucleic acid sensing pathways, and is part of the “IFN signature” associated with SLE.7,31 TNFAIP3 encodes the ubiquitin-editing enzyme A20, a negative regulator of NF-κB signaling, and its loss-of-function mutations have been associated with increased inflammatory responses and B cell activation.32 The lymphoid-specific protein tyrosine phosphatase (PTPN22) negatively regulates T cell receptor signaling; the R620W variant of the encoding gene inhibits PTPN22 expression, which in turn reduces the threshold for T cell activation and increases susceptibility to SLE and other autoimmune disorders.33 In addition, genetic variations in loci related to nucleic acid metabolism (e.g., TREX1), complement pathways (C1Q genes) and TLR signaling (TLR7 over-expression) have also been linked to SLE-relevant immune dysregulation.34 Polygenic risk scores and population-specific risks Conventional single-locus approaches cannot fully capture the polygenic landscape of SLE. Multi-ancestry GWAS and polygenic risk scores (PRS) incorporate hundreds of disease risk alleles weighted by the size of their effect, resulting in more accurate prediction of individual disease susceptibility. Furthermore, due to differences in allele frequencies and linkage structure among ethnic groups.35 For example, individuals of African and Asian ancestry carry a greater number of IFN and B cell risk alleles ancestry-tailored PRS can predict disease risk with greater accuracy compared to trans-ancestry models.28 In fact, the integration of PRS with clinical biomarkers, such as anti-dsDNA antibodies and complement, can significantly enhance the diagnostic accuracy and early-risk assessment of SLE.28 Thus, SLE-related genetic variations can be used to predict severe phenotypes, screen high-risk individuals or families, and identify patients who may benefit from targeted treatments.36 Epigenomic regulation in SLE Epigenomic disruption is a functional link between the genetic predisposition to a disease and environmental triggers such as ultraviolet (UV) radiation, viral infections, smoking, and hormonal exposures.37 Unlike static genetic modifications such as mutations, epigenetic changes, such as DNA methylation, histone modification, and non-coding RNAs-induced changes, are dynamic with respect to cell type and developmental stage. Therefore, it is reasonable to surmise that epigenetic changes in immune-related genes can significantly influence the pathogenesis of SLE.38 Over the last decade, various multi-omics analyses have characterized the epigenetic landscapes of SLE that contribute to the dysregulated activation of DCs, T cells, B cells, and neutrophils. Altogether, the epigenome of SLE is a key mechanistic driver of immune disruption in SLE, and a repository of potential biomarkers and drug targets.39 DNA methylation: Global hypomethylation and immune activation Aberrant DNA methylation is well-documented in SLE. Genome-wide profiling of CD4+ T cells, CD8+ T cells, B cells, and neutrophils has consistently demonstrated global DNA hypomethylation.27,40 In particular, hypomethylation of the IFN-stimulated genes (ISGs) primes their expression and maintains the IFN signature characteristic of SLE manifestations.8 Furthermore, immune-related genes such as IFI44L, MX1, OAS1, and IRF7 are demethylated in patients with SLE, and correlate with disease activity and organ damage. Environmental triggers can also exacerbate hypomethylation. For instance, exposure to UV light causes oxidative stress, which in turn inhibits DNA methyltransferase 1 (DNMT1) and leads to demethylation during mitosis.37,38 Global DNA hypomethylation in the autoreactive T cells activates genes that are normally repressed, including CD70, CD40L, and ITGAL.27 Likewise, hypomethylation of TLR and IFN pathway genes in neutrophils contributes to NET formation and tissue damage.8 Histone modifications: Chromatin accessibility and immune priming Chromatin access is regulated by post-translational modifications of histones, such as acetylation, methylation, and phosphorylation.41 Chromatin profiling of T cells and B cells from patients with SLE through ATAC-seq and ChIP-seq has identified altered histone marks at the enhancers or promoters of immune activation genes.39 For instance, increased abundance of H3K27ac and H3K4me3 at loci encoding cytokines (e.g., IL21 and IL6), costimulatory molecules, and IFN pathway regulators facilitates transcription.8 Conversely, repressive marks such as H3K27me3 are diminished in the loci promoting T cell exhaustion and effector differentiation, contributing to abnormal T cell polarization. Histone modifications also shape B cell dysfunction. Germinal center B cells from patients with SLE exhibit hyperacetylated enhancer regions in genes regulating somatic hypermutation and class-switch recombination, which is consistent with excessive autoantibody production.7 The dysregulated enhancer landscapes are further amplified by sustained type I IFN and IL-21 signaling, reinforcing pathogenic B cell states.39 MicroRNAs and immune circuitry MicroRNAs (miRNAs) are short, non-coding RNAs that post-transcriptionally regulate gene expression and play pivotal roles in immune homeostasis.39 Two of the most extensively studied miRNAs in SLE are miR-146a and miR-155, both of which modulate IFN and NF-κB pathways. MiR-146a acts as a negative regulator of innate immune signaling by targeting TRAF6 and IRAK1. Deficiency of miR-146a leads to unchecked type I IFN production and contributes to lymphocyte autoreactivity. Multiple SLE cohorts have shown reduced miR-146a expression in peripheral blood mononuclear cells, which strongly correlates with disease activity. In contrast, miR-155 is up-regulated in SLE and induces B cell activation, plasma cell differentiation, and development of follicular helper T (Tfh) cells, which culminate in the production of autoantibodies. Upregulation of miR-155 increases the expression of pro-inflammatory cytokines, and correlates with LN activity.8 In addition, miR-21, mirR-148a, and the miR-29 family simultaneously regulate DNA methylation, and contribute to the epigenetic control in SLE. Transcriptional dysregulation in immune cells Integrative transcriptomics has revealed widespread transcriptional rewiring across immune cell populations in SLE.12 scRNA-seq studies have identified age-associated B cells enriched for TLR7-driven programs, hyperactivated plasmablasts with expanded IFN-responsive transcription, Tfh cells skewed toward IL-21-producing states, DCs and monocytes with heightened nucleic acid-sensing and antigen-presenting signatures, and neutrophils with sustained NET-priming transcriptional profiles.8,9 Collectively, these transcriptional changes mirror the underlying epigenomic abnormalities in SLE and reinforce persistent immune activation even during clinical remission. Environmental and microbiome influences in SLE Emerging evidence implicates gut microbiota dysbiosis in SLE pathogenesis. Altered Firmicutes/Bacteroidetes ratios, reduced short-chain fatty acid-producing bacteria, and increased intestinal permeability may promote systemic immune activation and IFN signaling.42 Environmental pollutants, including particulate matter and endocrine-disrupting chemicals, have also been linked to epigenetic modifications that enhance autoreactive immune responses.43 Immune system dysregulation in SLE Dysregulation of the innate immune system Innate immune dysfunction is fundamental to SLE, as it drives and maintains the chronic autoimmune process, resulting in tissue inflammation and organ damage.44 The key features of immune dysregulation in SLE are neutrophil hyperactivation and NETosis, persistent activation of plasmacytoid dendritic cells (pDCs) with sustained production of type I IFNs, and aberrant signaling through nuclear acid-sensing PRRs, especially TLR7 and TLR9.45 Collectively, these innate defects generate a self-perpetuating inflammatory loop that drives the adaptive autoimmune response in SLE.44 NETosis and neutrophil dysfunction Neutrophils play a central role in the pathogenesis of SLE by generating NETs.46 While NETosis is a major defense mechanism against invading pathogens in healthy individuals, SLE is characterized by increased spontaneous and stimulated NETosis, which releases chromatin fibers decorated with oxidized mitochondrial DNA (mtDNA), histones, LL-37, and tissue-damaging peptidases.8 These NETs induce immune responses, and are resistant to DNase-mediated degradation due to the inhibitory effects of autoantibodies and complement fragments. Furthermore, the accumulated NETs release chromatin, histones, and proteases that activate pDCs, amplify type I IFN responses, stimulate autoreactive B cells, and promote endothelial damage, leading to endothelial injury, vasculopathy, and thrombosis.17 Low-density granulocytes (LDGs) constitute a pro-inflammatory subset of neutrophils that is expanded in SLE and displays enhanced NETosis. Increased abundance of LDGs is associated with more severe disease, including LN and neuropsychiatric involvement.7,17 NET-associated mtDNA also triggers cytosolic sensors, further enhancing inflammasome signaling and sustaining sterile inflammation.44 The NETosis cascade linking neutrophil dysfunction to systemic autoimmunity in SLE is illustrated in Figure 1.Figure 1The NETosis cascade in SLELow-density neutrophils undergo enhanced NETosis, releasing DNA, histones, and granule proteins that activate pDCs, amplify type I IFN responses, and provide autoantigens that perpetuate inflammation and tissue injury.7,47 Adapted with permission from © 2023 by the authors. Licensee MDPI, Basel, Switzerland. The NETosis cascade in SLE Low-density neutrophils undergo enhanced NETosis, releasing DNA, histones, and granule proteins that activate pDCs, amplify type I IFN responses, and provide autoantigens that perpetuate inflammation and tissue injury.7,47 Adapted with permission from © 2023 by the authors. Licensee MDPI, Basel, Switzerland. PDCs and the type I IFN loop The pDCs are the principal source of type I IFNs, which constitute one of the hallmark signatures of SLE.48 These cells are hyperresponsive to immune complexes containing nucleic acids, and their activation leads to sustained IFN-α/β production and transcriptional activation of the downstream ISGs.8 Persistent IFN signaling promotes DC maturation, enhances antigen presentation, primes autoreactive T cells, and drives B cell activation and plasmablast differentiation, thereby linking innate triggers to pathogenic autoantibody production.49 The “type I IFN loop” becomes self-reinforcing as NETs, apoptotic debris, and nucleic acid-containing immune complexes continually stimulate pDCs.48 High-resolution transcriptomic analyses show that this IFN-driven network spans monocytes, neutrophils, T cells, and B cells, establishing a pervasive inflammatory milieu in SLE even during clinical remission.9 The self-sustaining IFN loop observed in SLE is shown in Figure 2.Figure 2The type I IFN amplification loop in SLEThe PDCs activated by nucleic acid-containing immune complexes produce abundant type 1 IFNs, which activate monocytes, B cells, T cells, and neutrophils, and promote NETosis and immune complex formation, sustaining a self-amplifying pathogenic cycle associated with the IFN gene signature and elevated SIGLEC1 expression.3,7,9 The type I IFN amplification loop in SLE The PDCs activated by nucleic acid-containing immune complexes produce abundant type 1 IFNs, which activate monocytes, B cells, T cells, and neutrophils, and promote NETosis and immune complex formation, sustaining a self-amplifying pathogenic cycle associated with the IFN gene signature and elevated SIGLEC1 expression.3,7,9 Pattern recognition receptors involved in SLE TLR7 and TLR9, key innate sensors of ssRNA and unmethylated (UM) CpG DNA, respectively, are central to SLE pathogenesis50,51 Polymorphisms and increased transcription of TLR7 sensitize immune cells to RNA-carrying ligands, thereby tipping B cell and DC responses toward autoimmunity.7 Hyperactivity of TLR7 leads to the proliferation, class switching, and ANA production by autoreactive B cells.51In comparison, TLR9 counteracts TLR7-mediated autoimmunity in experimental models by controlling misdirected B cell activation.50 Immune complexes with self-DNA or RNA are taken up by Fcγ receptors inside endolysosomes, where they co-ligate TLR7/9 and trigger strong IFN- and NF-κB-dependent inflammatory responses.8 This PRR-dependent activation functions as an essential link between apoptotic debris, NETs, and systemic induction of immune dysregulation in SLE.52 Dysregulation of the adaptive immune system in SLE SLE is characterized by dysregulated adaptive immune responses, which result in the expansion of autoreactive lymphocytes, production of pathogenic autoantibodies, and activation of tissue-damaging inflammation.3 The core abnormalities include imbalances in T cell subtypes, and the hyperactivation of B cells and germinal centers, which contribute to long-lasting autoreactive plasma cells,53 that mediate the immunopathological changes in SLE.4,7 Imbalance in T cell subsets The T cell landscape in SLE is characterized by the expansion of Tfh cells, downregulation in Tregs, and increased generation of Th17 cells.54 The Tfh cells support B cell production in germinal centers, and are enriched in the peripheral blood and lymphoid organs of patients with SLE, with numbers correlatng with disease activity and autoantibody titers.7 The increased expression of IL-12 and inducible T cell co-stimulator (ICOS) on the Tfh cells leads to germinal center overactivity, resulting in the differentiation of autoreactive B cells into plasmablasts.53 Tregs are immunosuppressive cells that are required for maintaining tolerance. The Tregs in patients with SLE display altered metabolism and transcriptional signatures.54 Furthermore, type I IFN exposure and chronic inflammation disrupt Treg function, which allows autoreactive effector T cells to expand,8 and exacerbates the inflammatory response. B cell dysregulation and loss of tolerance B cell dysregulation is central to the pathogenesis of SLE.25,55 The impaired central, peripheral, and germinal center tolerance checkpoints promote the survival, maturation, and activation of autoreactive B cells.53 Excessive B cell receptor (BCR) signaling, high BAFF (BLyS) expression, and persistent IFN stimulation create a microenvironment that is conducive for the expansion of autoreactive clones. The transitional and naive B cells in patients with SLE also exhibit high levels of TLR7 signaling, which can lead to sustained activation without the need for BCR engagement.53,55 The autoreactive B cells not only secrete pathogenic antibodies, but also activate T cells by acting as antigen-presenting cells, and induce the production of inflammatory cytokines.56 The proliferation of age-associated B cells, an IFN-dependent T-bet-expressing subset, also promotes autoantibody production and correlates with LN and recalcitrant disease.8,53 Germinal center hyperactivity and long-lived plasma cells Germinal centers, the main location of affinity maturation and class switch recombination in B cells, are hyperactive and deregulated in SLE.55 Sustained Tfh-B cell interactions, hyper-stimulated IL-21 signaling, and reprogrammed follicular DC networks support the selection and prolonged survival of autoreactive B cells.7 Single-cell and in situ transcriptomic profiling have demonstrated accelerated cycling of B cells within SLE germinal centers, and identified an extended pool of pre-germinal center and early germinal center intermediates, which collectively promotes the continued generation of autoreactive plasmablasts.9 Long-lived plasma cells represent a significant hurdle to the treatment autoimmune diseases, as they remain in the bone marrow and inflamed tissues, and continue to secrete autoantibodies without exposure to antigen.25 These plasma cells are refractory to conventional immunosuppressive treatments as well as B cell depletion, and contribute to the pathogenesis of autoimmune diseases.8 Their longevity is indicative of the need for strategies focusing on plasma cell survival niches, or desensitization of supportive stromal signals.16,55 The interconnected innate and adaptive immune abnormalities central to SLE pathogenesis, including NET formation, pDC-driven type I IFN production, Tfh/Treg imbalance, autoreactive B cell activation, and autoantibody production, have been summarized in Figure 3.55Figure 3The interplay between innate and adaptive immune dysregulation in SLENETotic neutrophils, pDC-driven type I IFN loops, Tfh/Treg imbalance, and autoreactive B cell activation converge to drive autoantibody production and immune complex-mediated organ injury.3,7 ABCA1: ATP-binding cassette transporter A1; ABCG1: ATP-binding cassette transporter G1; APC: antigen-presenting cell; IL: interleukin; MHC: major histocompatibility complex; TCR: T cell receptor; TNF-α: tumor necrosis factor alpha. Adapted with permission from © 2017 by the authors. Licensee MDPI, Basel, Switzerland. The interplay between innate and adaptive immune dysregulation in SLE NETotic neutrophils, pDC-driven type I IFN loops, Tfh/Treg imbalance, and autoreactive B cell activation converge to drive autoantibody production and immune complex-mediated organ injury.3,7 ABCA1: ATP-binding cassette transporter A1; ABCG1: ATP-binding cassette transporter G1; APC: antigen-presenting cell; IL: interleukin; MHC: major histocompatibility complex; TCR: T cell receptor; TNF-α: tumor necrosis factor alpha. Adapted with permission from © 2017 by the authors. Licensee MDPI, Basel, Switzerland. Autoantibody generation and immune complexes in SLE The key pathological drivers of SLE are autoantibody generation and tissue damage due to the formation of immune complexes.37 The interaction between Tfh cells and auto-reactive B cells leads to excessive germinal center activity, resulting in the production of anti-nuclear antibody (ANA) that causes inflammatory damage.7,8 The circulating levels of anti-dsDNA, anti-Sm, and anti-C1q autoantibodies are reliable serological indicators of SLE.57 Key autoantibodies of SLE Anti-dsDNA antibodies represent some of the best characterized and disease-specific markers for SLE, and their presence strongly correlates with disease severity and the risk of LN.58 The serological titers of anti-dsDNA antibodies also reflect the renal inflammatory load from the immune complexes deposited in the glomerulus.59 Different isotypes of these autoantibodies have been detected, of which the IgG forms show the strongest correlation with complement activation and renal damage.60 Anti-Sm antibodies target proteins in small nuclear ribonucleoprotein complexes, and are specific for SLE.23,57 Although not closely related to disease activity, anti-Sm antibodies are indicative of deep derangements in B cell selection, particularly for RNA self-antigens.7,53 Furthermore, their presence is associated with disturbed germinal center reaction and long-lived autoreactive plasma cells. Anti-C1q antibodies are directed toward the collagen-like region of C1q, which is involved in the removal of apoptotic debris.37 These autoantibodies interfere with the phagocytosis of apoptotic cells – the functional equivalent of inherited C1q deficiency, which is one of the most potent genetic risk factors for SLE.61 Anti-C1q antibodies are specifically related to proliferative LN, renal flares, and low levels of complement. Immune complex formation, tissue deposition, and organ injury Autoantibodies attach to exposed nuclear antigens that are released by NETosis and defective apoptosis clearance. The resulting immune complexes circulate in the bloodstream,37 and accumulate in the kidneys, skin, vasculature, and central nervous system, where they activate the classical complement pathway and bind to Fc receptors expressed on resident and infiltrating immune cells.59,62 Complement activation results in the production of C3a and C5a anaphylatoxins, which promote recruitment of leukocytes and exacerbate local inflammation.23 The deposition of immune complexes containing dsDNA and C1q in the glomerular basement membranes induce a form of glomerulonephritis that manifests as endocapillary proliferation, neutrophil infiltration, and podocyte injury.59,63 Complement-dependent cytotoxicity and inflammation further damage renal tissue, leading to proteinuria, decreased filtration, and chronic fibrosis.7 Impaired clearance of apoptotic debris due to defective DNase activity, complement dysregulation, and sustained type I IFN signaling lead to the persistence of autoantigens. This leads to the continued production of autoantibodies and deposition of immune complexes, thereby establishing a self-amplifying loop that underlies chronic SLE pathology.8,37 Figure 4 illustrates how defective clearance of apoptotic and NET-derived nuclear antigens drives autoreactive B-cell activation, germinal center hyperactivity, and the production of pathogenic autoantibodies (e.g., anti-dsDNA and anti-Sm), leading to immune complex deposition and tissue damage.63Figure 4Self-amplifying autoantibody generation in SLEDysregulated clearance of apoptotic and NET-derived nuclear antigens activates DCs and drives type I IFN production. Autoreactive B cells are activated by the Tfh cells in germinal centers, undergo somatic hypermutation, and differentiate into long-lived plasma cells that secrete pathogenic autoantibodies (e.g., anti-dsDNA, anti-Sm, and anti-C1q). Immune complexes deposit in tissues, activate complement, and propagate inflammation and organ damage.7,60 © Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license. Self-amplifying autoantibody generation in SLE Dysregulated clearance of apoptotic and NET-derived nuclear antigens activates DCs and drives type I IFN production. Autoreactive B cells are activated by the Tfh cells in germinal centers, undergo somatic hypermutation, and differentiate into long-lived plasma cells that secrete pathogenic autoantibodies (e.g., anti-dsDNA, anti-Sm, and anti-C1q). Immune complexes deposit in tissues, activate complement, and propagate inflammation and organ damage.7,60 © Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license. Collectively, these innate and adaptive immune perturbations form the mechanistic substrate underlying organ-specific pathology in SLE. The convergence of NET-derived autoantigens, sustained type I IFN signaling, Tfh-driven germinal center hyperactivity, and autoreactive plasma cell persistence provides a direct pathogenic bridge to immune complex deposition and cytokine amplification within target tissues, as discussed in the following section.55 Organ system involvement in SLE Renal disease LN is one of the most severe complications of SLE, and contributes substantially to morbidity and long-term renal failure. Almost 60% of patients with SLE develop LN, and the disease burden is especially high in individuals of African, Hispanic, and Asian descent.7 Renal involvement is a manifestation of both systemic autoimmunity and local immunopathology resulting from immune complex deposition and complement activation. Pediatric-onset SLE (cSLE) is frequently associated with more aggressive nephritis, higher IFN signatures, and increased neuropsychiatric involvement compared to adult-onset disease.64 However, therapeutic decisions in cSLE are often extrapolated from adult trials, underscoring the need for pediatric-specific mechanistic and clinical studies. Histopathological and molecular classification Immune-mediated LN is categorized by ISN/RPS 2018 into six classes based on glomerular involvement, ranging from mild mesangial disease (classes I–II) to proliferative (classes III–IV) and membranous (class V) forms.62 Proliferative LN is characterized by endocapillary hypercellularity, wire-loop lesions, crescents, and widespread immune complex deposition, while Class V disease presents subepithelial deposits similar to those observed in membranous nephropathy.62 Nevertheless, histological classification alone cannot encompass the full spectrum of LN heterogeneity. Recent advances in single-cell transcriptomics and spatial profiling have uncovered molecular subtypes of LN categorized on the basis of type I IFNs, NF-κB activation, metabolic reprogramming, and aberrant metabolism of myeloid cell populations.8,9 Compared to the histopathological markers, molecular profiles of LN can better distinguish the treatment responders from non-responders, and predict prognosis with greater accuracy. Multi-omics approaches have demonstrated persistent IFN and fibrotic signatures in the renal tissues of patients with LN, which predict the progression to chronic kidney disease even when clinical remission has been achieved.20 The histopathological features and clinical manifestations of the different classes of LN have been summarized in Figure 5.Figure 5Histological classification of LN based on ISN/RPS criteriaClasses I-VI represent the spectrum of disease from minimal mesangial involvement to diffuse proliferative disease and advanced sclerosis.65 Adapted from Ana Cristina Simões e Silva. Pediatric lupus nephritis. J Bras Nefrol. 41 (2) Apr-Jun 2019. https://doi.org/10.1590/2175-8239-JBN-2018-0097 © Sociedade Brasileira de Nefrologia. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Histological classification of LN based on ISN/RPS criteria Classes I-VI represent the spectrum of disease from minimal mesangial involvement to diffuse proliferative disease and advanced sclerosis.65 Adapted from Ana Cristina Simões e Silva. Pediatric lupus nephritis. J Bras Nefrol. 41 (2) Apr-Jun 2019. https://doi.org/10.1590/2175-8239-JBN-2018-0097 © Sociedade Brasileira de Nefrologia. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The distinguishing features include mesangial hypercellularity, subendothelial and subepithelial deposits, wire-loop lesions, crescents, and global sclerosis, which are summarized for rapid comparative interpretation.12,14 Cytokines and local immune infiltrates Kidney inflammation in patients with SLE is the result of increased cytokine production and infiltration of immune cells. High levels of IL-6, BAFF, IFN-α, and IL-17 promote B cell maturation, T cell activation, and mesangial proliferation.66 Furthermore, the IFN-α-producing pDCs amplify local immune activation, and the intrarenal macrophages and neutrophils cause tissue injury via NETosis, oxidative stress, and protease release.8 Single-cell immune profiling has demonstrated pathogenic B cell and plasma cell niches in the tubulointerstitial areas of patients with LN, which produce anti-dsDNA and anti-C1q antibodies,67 and are associated with poor treatment response and fibrosis.9 Renal injury is also mediated by T cell subsets including Tfh-like cells, inflammatory Th17 cells, and cytotoxic CD8+ T cells through cytokine production and direct cytotoxicity.63 The major cytokines involved in LN pathogenesis include type I IFNs, BAFF/APRIL, IL-21, IL-6, IL-17, IL-2, and IL-10, which amplify inflammation and break immune tolerance by orchestrating the crosstalk between DCs, T cells, B cells, and neutrophils (Figure 6).Figure 6Cytokine interaction network driving inflammation in SLEIn systemic lupus erythematosus (SLE), antigen-presenting cells (APCs) secrete IL-6 and IL-23 upon immune activation. IL-6 signals via membrane-bound IL-6 receptor (IL-6R) or soluble IL-6 receptor (sIL-6R) shed from polymorphonuclear leukocytes (PMNs), activating STAT3 phosphorylation (P-STAT3) in target cells. In the presence of TGF-β, IL-6-driven P-STAT3 promotes the differentiation of naive CD4+ T cells into Th17 cells rather than regulatory T cells (Tregs), skewing immune balance toward a pro-inflammatory phenotype. IL-23, produced by APCs, stabilizes and expands the Th17 population by binding IL-23R and sustaining STAT3 signaling. Activated Th17 cells produce IL-17, which stimulates stromal cells to produce chemokines via NF-κB activation, recruiting additional PMNs and immune cells to sites of inflammation. This self-amplifying loop drives immune cell infiltration and tissue damage, contributing to lupus nephritis and other end-organ manifestations in SLE. Adapted with permission from Valeria Poli et al., IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?, 2012, DOI: 10.2741/4054. Cytokine interaction network driving inflammation in SLE In systemic lupus erythematosus (SLE), antigen-presenting cells (APCs) secrete IL-6 and IL-23 upon immune activation. IL-6 signals via membrane-bound IL-6 receptor (IL-6R) or soluble IL-6 receptor (sIL-6R) shed from polymorphonuclear leukocytes (PMNs), activating STAT3 phosphorylation (P-STAT3) in target cells. In the presence of TGF-β, IL-6-driven P-STAT3 promotes the differentiation of naive CD4+ T cells into Th17 cells rather than regulatory T cells (Tregs), skewing immune balance toward a pro-inflammatory phenotype. IL-23, produced by APCs, stabilizes and expands the Th17 population by binding IL-23R and sustaining STAT3 signaling. Activated Th17 cells produce IL-17, which stimulates stromal cells to produce chemokines via NF-κB activation, recruiting additional PMNs and immune cells to sites of inflammation. This self-amplifying loop drives immune cell infiltration and tissue damage, contributing to lupus nephritis and other end-organ manifestations in SLE. Adapted with permission from Valeria Poli et al., IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?, 2012, DOI: 10.2741/4054. The crosstalk between pDCs, T cells, neutrophils, and B cells amplifies inflammation, breaks immune tolerance, and drives autoantibody production in the renal tissues. The major therapeutic targets are shown at the relevant cytokine nodes.68 Taken together, histopathological findings combined with transcriptomic and cellular signatures create a more accurate framework for LN classification, prognosis, and targeted personalized therapy. Neuropsychiatric manifestations of SLE The central and peripheral nervous system manifestations of SLE are grouped under neuropsychiatric SLE (NPSLE), which ranges from cognitive dysfunction to psychosis. Other clinical manifestations of NPSLE include seizure disorders, headache syndromes, peripheral neuropathies, and cerebrovascular diseases.69 The pathogenesis of NPSLE is complex, and involves autoantibody-mediated neural injury, micro vascular inflammation, breakdown of the blood-brain barrier (BBB), and the generation of neuroinflammatory cascades.7 Autoimmune neuroinflammation The anti-NMDAR (anti-NR2), anti-phospholipid, and anti-ribosomal P autoantibodies promote neuroexcitotoxicity, thrombosis, and abnormal neurotransmission respectively.23,47 Furthermore, the disruption of the BBB by cytokines such as IL-6 and IFN-α, NET-associated proteases, and endothelial dysfunction allows peripheral immune complexes and inflammatory mediators to reach nervous system tissues.20,62 The activated microglia then trigger neuronal damage by generating reactive oxygen species, complement elements, and pro-inflammatory cytokines.47 In addition, systemic IFN activation influences neuronal metabolic pathways, synaptic homeostasis, and neurogenesis to modulate neuroinflammation.47 Recent transcriptomic studies show altered ISG and microglial activation signatures in patients with NPSLE, which is consistent with the transcriptomic profile of their peripheral immune system.8 Imaging and biomarker correlates Recent advances in neuroimaging have improved our understanding of NPSLE pathogenesis.20 For instance, diffusion tensor imaging indicates white substance microstructural abnormality in patients with NPSLE, while functional magnetic resonance imaging shows altered connectivity in memory-executive networks.20 In addition, positron tomography images of the brain from patients with active NPSLE indicate significant neuroinflammation.20 Biomarkers such as neurofilament light chain, complement proteins, and cytokines are associated with disease activity and cognitive disability, but none of them have been fully validated for standard clinical application.14,20 Overall, neuropsychiatric symptoms represent complex interactions among systemic autoimmunity and neural-specific immune pathways, which warrant targeted diagnostics and therapeutics. Dermatological and mucosal disease Cutaneous lupus erythematosus (CLE) is a common organ-specific manifestation of SLE, and includes acute, subacute, and chronic forms with different immunopathological features.47 Acute CLE, for e.g., malar rash, correlates with marked type I IFN activation, high titers of ANA and anti-dsDNA antibodies, and interface dermatitis with vacuolar degeneration of basal keratinocytes.8 Subacute CLE is closely associated with anti-Ro/SSA antibodies, and characterized by dense T cell infiltrates, enhanced CXCL9/10 signaling and apoptotic keratinocytes.70 Chronic CLE, specifically discoid lupus, exhibits folliculotropic inflammation, pDC infiltration, and fibrosis, which collectively indicate persistent IFN-mediated keratinocyte damage.71 Mucocutaneous involvement, including oral, nasal, and vulvar ulcers, occurs due to localized immune complex-mediated vasculopathy and type I IFN production.47,70 Transcriptomic profiling of CLE lesions has identified subtype-specific inflammatory circuits, such as JAK-STAT signaling activation and abnormal TLR7/9 pathways, suggesting potential therapeutic targets.70 Overall, cutaneous manifestations of SLE represent widespread immune dysregulation and frequently correlate with systemic disease activity, and can therefore predict flares. Cardiopulmonary, hematological, and musculoskeletal involvement The involvement of the cardiopulmonary, hematological, and musculoskeletal systems in SLE disease plays a sizable role in long-term morbidity. Atherosclerosis Cardiovascular disease is the second leading cause of mortality in SLE, and the result of chronic inflammation, type I IFN signaling, endothelial dysfunction, oxidative stress, and steroid exposure.7 IFN-mediated metabolic reprogramming impairs cholesterol efflux and enhances foam cell formation, whereas NET-derived oxidized lipids promote plaque instability. Furthermore, patients with SLE have a 2- to 10-fold higher risk of developing myocardial infarction compared to age-matched controls.62 Novel imaging modalities, such as coronary CT angiography and PET tracers for vascular inflammation, have uncovered subclinical atherosclerosis even in young individuals with SLE. Cytopenia Autoantibody-mediated opsonization and complement activation in SLE can also cause hematological hypoplasia, seizure, fever, anemia, thrombocytopenia, and hemolysis.17The anti-RBC, anti-platelet, and anti-neutrophil antibodies have been implicated in SLE-related cytopenia, and the production of these autoantibodies is sustained through type I IFN and BAFF-driven B cell maturation.8 Single-cell analysis of the bone marrow of patients with SLE shows the expansion of IFN-primed progenitors and aberrant myelopoiesis. Furthermore, thrombocytopenia in SLE is increasingly being linked to T cell-mediated platelet cytotoxicity and dysregulated megakaryopoiesis. Arthralgia and non-erosive arthritis are common complications of SLE, and are triggered by immune complex deposition, activation of synovial macrophages, and IL-6/IL-17-driven inflammation. Unlike rheumatoid arthritis, SLE-related arthritis is typically not accompanied by bone erosion, although erosive “rhupus” variants have been reported. Transcriptomic profiling of the synovial tissues of patients with SLE reveals significant enrichment of ISGs and complement activation pathways, along with the expansion of T peripheral helper (Tph) cells and age-associated B cells, implicating ectopic germinal center formation in persistent synovitis.9 Furthermore, type I IFN-driven myofiber injury and complement-mediated microangiopathy can lead to myositis in patients with SLE. Table 1 summarizes organ-specific biomarkers and their clinical implications.Table 1Organ-specific biomarkers and clinical implications in SLEOrgan SystemKey BiomarkersClinical Utility (Diagnosis, Monitoring, Prognosis)Mechanistic/Pathophysiologic NotesRepresentative References (APA in-text)Renal (Lupus Nephritis)anti-dsDNA, anti-C1qdiagnose LN; correlates strongly with active proliferative classesreflect immune complex deposition and complement activationCalatroni et al.72complement C3/C4monitoring LN flares; low levels predict relapseconsumption reflects circulating immune complexesLindblom et al.14urinary MCP-1, NGALsensitive early markers of renal inflammation and tubular injuryMCP-1 reflects monocyte recruitment; NGAL detects tubular stressGreenan-Barrett et al.22ALCAM, CD163, VCAM-1track intrarenal macrophage activation; predict treatment responsedescribe endothelial/microenvironmental injuryAnthony et al.73IFN-driven gene signatures (MX1, IFIT1)distinguish active vs. quiescent LNlinked to plasmacytoid DC activationHaynes et al.12Neuropsychiatric (NPSLE)anti-NMDA receptor antibodiessupport suspected autoimmune neurotoxicitytrigger excitotoxic neuronal injuryManca74anti-ribosomal Pspecific for lupus psychosis and mood disordersassociated with neuronal surface bindingHo et al.75CSF IL-6, neurofilament light chaintrack CNS inflammation and axonal injuryreflect blood-brain barrier disruptionDeijns et al.47MRI lesions, HRVWI markersdetect small-vessel vasculopathy and neuroinflammationcapture microvascular pathology not seen on CTAMatos et al.76Dermatologic (CLE)type I IFN-inducible keratinocyte signaturesdistinguish CLE subtypes; reflect activityIFN drives keratinocyte apoptosis and interface dermatitisStannard and Kahlenberg77CXCL9/CXCL10 (skin biopsies)predict treatment response and severityproduced by keratinocytes and infiltrating T cellsMaz and Michelle Kahlenberg78HLA risk alleles (HLA-DQA1, DRB1)stratify risk for SCLEencode antigen-presentation differencesHersh et al.79Cardiovascular/Atherosclerosisantiphospholipid antibodies (aCL, anti-β2GPI, LA)diagnose APS; assess thrombosis riskpromote endothelial activation and clot formationLu et al.50VEGF, VCAM-1, ICAM-1detect endothelial injury and early atherosclerosisreflect vascular inflammation and plaque instabilityBlachut et al.80carotid intima-media thickness (CIMT)detect subclinical atherosclerosissensitive early structural biomarkerWu et al.81Hematologiclymphopenia, low complementincluded in SLEDAI; reflect disease activityT cell exhaustion and complement consumptionIdborg and Oke68anti-Ro, anti-ribosomal Plinked to hemolytic anemiaautoantibody-mediated destructionLu et al.50cytokines (IL-6, IFN signature)predict cytopenias during flaresdrive bone marrow suppression and peripheral destructionHuang et al.54Musculoskeletalanti-CCP subset, cytokine profiles (IL-17, IL-23)stratify erosive vs. non-erosive arthritisIL-17-driven synovitis resembles RA-like pathwaysCeccarelli et al.82MRI/ultrasound synovitisdetect early joint inflammationidentify subclinical erosive diseaseCeccarelli et al.82bone turnover markers (CTX, PINP)monitor glucocorticoid-induced bone losstrack metabolic bone changesMorand et al.83(Fully original; no copyright restrictions). Table 1Organ-specific biomarkers and clinical implications in SLEOrgan SystemKey BiomarkersClinical Utility (Diagnosis, Monitoring, Prognosis)Mechanistic/Pathophysiologic NotesRepresentative References (APA in-text)Renal (Lupus Nephritis)anti-dsDNA, anti-C1qdiagnose LN; correlates strongly with active proliferative classesreflect immune complex deposition and complement activationCalatroni et al.72complement C3/C4monitoring LN flares; low levels predict relapseconsumption reflects circulating immune complexesLindblom et al.14urinary MCP-1, NGALsensitive early markers of renal inflammation and tubular injuryMCP-1 reflects monocyte recruitment; NGAL detects tubular stressGreenan-Barrett et al.22ALCAM, CD163, VCAM-1track intrarenal macrophage activation; predict treatment responsedescribe endothelial/microenvironmental injuryAnthony et al.73IFN-driven gene signatures (MX1, IFIT1)distinguish active vs. quiescent LNlinked to plasmacytoid DC activationHaynes et al.12Neuropsychiatric (NPSLE)anti-NMDA receptor antibodiessupport suspected autoimmune neurotoxicitytrigger excitotoxic neuronal injuryManca74anti-ribosomal Pspecific for lupus psychosis and mood disordersassociated with neuronal surface bindingHo et al.75CSF IL-6, neurofilament light chaintrack CNS inflammation and axonal injuryreflect blood-brain barrier disruptionDeijns et al.47MRI lesions, HRVWI markersdetect small-vessel vasculopathy and neuroinflammationcapture microvascular pathology not seen on CTAMatos et al.76Dermatologic (CLE)type I IFN-inducible keratinocyte signaturesdistinguish CLE subtypes; reflect activityIFN drives keratinocyte apoptosis and interface dermatitisStannard and Kahlenberg77CXCL9/CXCL10 (skin biopsies)predict treatment response and severityproduced by keratinocytes and infiltrating T cellsMaz and Michelle Kahlenberg78HLA risk alleles (HLA-DQA1, DRB1)stratify risk for SCLEencode antigen-presentation differencesHersh et al.79Cardiovascular/Atherosclerosisantiphospholipid antibodies (aCL, anti-β2GPI, LA)diagnose APS; assess thrombosis riskpromote endothelial activation and clot formationLu et al.50VEGF, VCAM-1, ICAM-1detect endothelial injury and early atherosclerosisreflect vascular inflammation and plaque instabilityBlachut et al.80carotid intima-media thickness (CIMT)detect subclinical atherosclerosissensitive early structural biomarkerWu et al.81Hematologiclymphopenia, low complementincluded in SLEDAI; reflect disease activityT cell exhaustion and complement consumptionIdborg and Oke68anti-Ro, anti-ribosomal Plinked to hemolytic anemiaautoantibody-mediated destructionLu et al.50cytokines (IL-6, IFN signature)predict cytopenias during flaresdrive bone marrow suppression and peripheral destructionHuang et al.54Musculoskeletalanti-CCP subset, cytokine profiles (IL-17, IL-23)stratify erosive vs. non-erosive arthritisIL-17-driven synovitis resembles RA-like pathwaysCeccarelli et al.82MRI/ultrasound synovitisdetect early joint inflammationidentify subclinical erosive diseaseCeccarelli et al.82bone turnover markers (CTX, PINP)monitor glucocorticoid-induced bone losstrack metabolic bone changesMorand et al.83(Fully original; no copyright restrictions). Organ-specific biomarkers and clinical implications in SLE (Fully original; no copyright restrictions). Biomarkers and multi-omics integration in SLE It is crucial to identify reliable biomarkers of SLE in order to improve diagnosis, patient stratification, and precision therapeutics.84 Given the significant heterogeneity of SLE, no single biomarker can fully capture disease activity or predict flares. Recent advances in systems immunology, proteomics, and single-cell technologies are enabling the construction of multi-dimensional diagnostic and prognostic models for SLE that integrate molecular signatures with clinical trajectories.7,12 Traditional biomarkers of SLE Serum ANA is the key diagnostic marker of SLE; although the sensitivity of the ANA blood test exceeds 95%, the specificity is very low, particularly for early or overlapping disease.60 On the other hand, anti-dsDNA antibodies show greater specificity for SLE, and correlate with disease activity and renal manifestations, particularly proliferative LN. Increased levels of dsDNA antibodies are often associated with changes in complement C3 and C4, indicating immune complex formation and consumption.14 Although these markers are the current standard in clinical diagnosis of SLE, they have poor predictive power for future flares, and discordance between serial dsDNA titers and symptoms suppresses biomarkers to deliver more robust metrics at the molecular level.84 Complement split products (e.g., C3a, C4d, and Bb) have demonstrated better performance than conventional complement measurements, but are largely limited to experimental settings. Altogether, while ANA, dsDNA antibody, and complement levels are essential markers for routine SLE follow-up, their limitations warrant new generation markers. IFN signatures and SIGLEC1 The activation of type I IFN is a central feature in the pathogenesis of SLE. As a result, ISGs are among the most reproducible molecular features of SLE across ancestry, age, and disease subsets,8 and are associated with disease activity, mucocutaneous findings, hematological signs, and treatment recalcitrance. Therefore, IFN signatures can be used to screen for patients more likely to benefit from IFN-targeted therapeutics.17 Sialic acid-binding Ig-like lectin 1 (SIGLEC1), a cell adhesion molecule expressed on monocytes, is a surrogate marker of type I IFN pathway activation.85 Increased SIGLEC1 expression is associated with renal disease, hematological abnormalities, and overall SLE activity, and decreases upon IFN pathway inhibition.68 Compared to transcriptomic IFN signatures, SIGLEC1 is a more practical clinical biomarker, although the cut-off values remain to be standardized. On the other hand, IFN-related biomarkers may be persistently elevated in patients with SLE despite clinical remission, indicating that IFN activation is required but not sufficient for flares.86 Therefore, combining IFN signatures with conventional SLE biomarkers may improve risk stratification.84 Proteomics and single-cell transcriptomics High-dimensional proteomics has accelerated the identification of novel biomarkers for SLE, LN, and NPSLE.87 For example, neutrophil gelatinase-associated lipocalin (NGAL), CD163, ALCAM, and VCAM-1 are markers of tubular injury, macrophage activity, and endothelial dysfunction.88 Urinary proteomic panels including these markers have shown robust predictive performance for LN flares, histopathological class, and treatment response, although only a handful have advanced into clinical use.89 Furthermore, scRNA-seq studies have unearthed various cell type-specific transcriptional abnormalities that were overlooked in previous bulk tissue analyses.90 In a recent study, analysis of the scRNA-seq data of >1 million immune cells from patients with SLE revealed that the IFN-high and myeloid-activated molecular subtypes were tightly linked to genetic risk variants and clinical phenotypes.9 These observations underscore the convergent nature of genetic susceptibility on cell-type-specific inflammatory programs. Furthermore, scRNA-seq and multi-omics studies have shown that the age-associated expansion of B cells or Tph cells in active disease, defective pDCs activation and epigenomic training, and robust transcriptional signatures at the time of remission are suggestive of relapse. Finally, spatial transcriptomics have identified the IFN, complement and fibrotic pathway networks that drive organ damage in SLE by mapping tissue-specific immune niches, including kidney tubulointerstitiual infiltrates.13 Biomarker-driven patient stratification The combination of traditional serological markers and multi-omics biomarkers is redefining SLE classification and therapeutic approaches. Multi-biomarker phenotyping with dsDNA antibodies, complement levels, IFN signatures, and BAFF/BLyS expression delineates biologically coherent subgroups of SLE associated with different risks of flare and organ damage.14 For example, IFN-high patients often exhibit mucocutaneous disease, cytopenias, and better response to anifrolumab, while BLyS-high patients may respond more favorably to B cell-directed therapy such as belimumab.91 In addition, complement-low/dsDNA-high profiles often predict LN flares and the need for early immunosuppression. ML applications have further refined the stratification of SLE patients. Whole-blood RNA-seq combined with unsupervised clustering has now identified subtypes of SLE characterized by neutrophil-dominant, IFN-dominant, B cell-led or metabolic signatures. These molecular clusters predict clinical course, drug treatment, and response to biologics. Furthermore, predictive models consisting of immune-gene hubs such as CXCL2, CXCL8, and NFKBIA have been validated across cohorts for early diagnosis.26 PRS are also being incorporated into SLE biomarker panels. Multi-ancestry GWAS meta-analyses have yielded PRS models that improve diagnosis accuracy while distinguishing high-risk ancestries, such as individuals of East Asian and African descent who are overrepresented in severe SLE cases.28 PRS-directed stratification could aid personalized surveillance and prevention strategies. This integrated framework combines traditional serological markers with pathway-specific, organ-specific, and multi-omics biomarkers to enable patient stratification, flare prediction, and precision therapeutic development (Figure 7).Figure 7Roadmap of traditional, pathway-specific, organ-specific, and multi-omics biomarkers of SLEFoundational clinical markers (ANA, anti-dsDNA, C3/C4) can be integrated with IFN signatures, NET-related biomarkers, cytokine panels, and organ-focused indicators (e.g., NGAL, CD163, and anti-NMDA-R). Adapted with permission from © 2024 by the authors. Licensee MDPI, Basel, Switzerland. Roadmap of traditional, pathway-specific, organ-specific, and multi-omics biomarkers of SLE Foundational clinical markers (ANA, anti-dsDNA, C3/C4) can be integrated with IFN signatures, NET-related biomarkers, cytokine panels, and organ-focused indicators (e.g., NGAL, CD163, and anti-NMDA-R). Adapted with permission from © 2024 by the authors. Licensee MDPI, Basel, Switzerland. Advanced multi-omics approaches including genomics, epigenomics, proteomics, and single-cell transcriptomics enable fine-grained patient stratification, predictive modeling, and precision therapy development.14,15 Table 2 integrates systemic, multi-omics, and prognostic markers relevant to precision stratification.Table 2Diagnostic, and prognostic biomarkers of SLEBiomarker ClassBiomarker(s)Diagnostic UtilityMonitoring ValuePrognostic ImplicationsKey References (APA in-text)Traditional Serologic MarkersANAhighly sensitive; required for classificationnot reliable for activity monitoringlimited prognostic valuePisetsky and Lipsky60anti-dsDNAspecific for SLE; strong association with nephritistracks renal activity; rises before flareshigh titers predict severe renal involvementPisetsky and Lipsky60; Idborg and Oke68anti-Smhighly specific but low sensitivityrarely useful for monitoringmarks more severe systemic diseaseGómez-Bañuelos et al.92complement C3/C4consumption indicates active immune complex diseasedecline precedes flares; useful in LNlow complement predicts renal flare riskLindblom et al.14Autoantibody Panelsanti-C1qsupports the diagnosis of active LNstrong correlation with renal disease activitypredicts renal flares and poor LN outcomesCalatroni et al.72antiphospholipid antibodies (aCL, anti-β2GPI, LA)diagnostic for APS; found in the SLE subsetmonitor thrombosis riskpredict thrombosis, pregnancy loss, and CVDPan et al.50Interferon-Related Biomarkerstype I IFN signature (ISG15, MX1, IFIT1)distinguishes SLE from other autoimmune diseasestracks systemic inflammation and skin activityhigh IFN scores predict severe extrarenal diseaseCaielli et al.8; Haynes et al.12SIGLEC1 (CD169)surrogate marker of IFN activationhighly responsive to changes in the IFN pathwayelevated levels correlate with disease severityIdborg and Oke68Innate Immune Activation BiomarkersNET components (cfDNA, MPO-DNA, NE-DNA)reflect abnormal NETosis seen in SLEincrease during flares, especially LNhigh levels predict renal injury and vascular riskGuan et al.93IL-6, IL-18, IP-10, MCP-1elevated in active inflammatory statesuseful for monitoring LN and NPSLEhigh cytokine levels are linked to flares and organ damageHuang et al.54; Wu et al.94Renal Injury Biomarkers (LN)NGALearly tubular injury markertracks renal flare and treatment responsepredicts CKD progressionGreenan-Barrett et al.22MCP-1 (urinary)sensitive LN biomarkerreflects intrarenal inflammationpredicts flare severityAnthony et al.73ALCAM, CD163, VCAM-1reflect intrarenal macrophage and endothelial activationeffective LN activity markerspredicts response to therapy and relapsePalazzo et al.67Neuropsychiatric Biomarkersanti-NMDA receptor antibodiessupports the diagnosis of NPSLEtracks cognitive dysfunction in some patientspotential marker of neurotoxicity riskManca74anti-ribosomal Phighly specific for psychosis and mood disordersuseful in specific presentationspredicts NPSLE manifestationsHo et al.75CSF IL-6, neurofilament light chainreflect CNS inflammation and axonal injurysensitive to active NPSLEelevated values predict poorer outcomesDeijns et al.47Cutaneous Lupus BiomarkersIFN-inducible keratinocyte signaturesdistinguish CLE subtypesreflect skin disease activitypredict progression to systemic diseaseStannard and Kahlenberg77Genomic and Polygenic Markerspolygenic risk scores (PRS)predict SLE susceptibilitylimited value for activityhigh PRS linked to severe multi-organ involvementKhunsriraksakul et al.28Epigenetic and Transcriptomic MarkersDNA methylation patternsdistinguish SLE from controlsreflect immune dysregulationmethylation signatures predict flare riskWang et al.95miR-146a, miR-155reflect TLR/IFN pathway activitytrack inflammation and LNassociated with severity and damage accrualWu et al.94SLE MetaSignature/SLEmetaSig100high diagnostic accuracy across cohortsstable across disease states; useful for monitoringstratifies patients by molecular phenotypeHaynes et al.12Proteomic Biomarkerscomplement fragments, acute phase reactantscontribute to multi-analyte disease panelstrack systemic inflammationpredict organ involvementPerez et al.9Machine Learning-Derived Biomarkersautoantibody signature clustersidentify phenotypes of organ riskuseful for flare predictionpredict mortality and treatment responseChoi et al.15(Fully original, no copyright restrictions). Table 2Diagnostic, and prognostic biomarkers of SLEBiomarker ClassBiomarker(s)Diagnostic UtilityMonitoring ValuePrognostic ImplicationsKey References (APA in-text)Traditional Serologic MarkersANAhighly sensitive; required for classificationnot reliable for activity monitoringlimited prognostic valuePisetsky and Lipsky60anti-dsDNAspecific for SLE; strong association with nephritistracks renal activity; rises before flareshigh titers predict severe renal involvementPisetsky and Lipsky60; Idborg and Oke68anti-Smhighly specific but low sensitivityrarely useful for monitoringmarks more severe systemic diseaseGómez-Bañuelos et al.92complement C3/C4consumption indicates active immune complex diseasedecline precedes flares; useful in LNlow complement predicts renal flare riskLindblom et al.14Autoantibody Panelsanti-C1qsupports the diagnosis of active LNstrong correlation with renal disease activitypredicts renal flares and poor LN outcomesCalatroni et al.72antiphospholipid antibodies (aCL, anti-β2GPI, LA)diagnostic for APS; found in the SLE subsetmonitor thrombosis riskpredict thrombosis, pregnancy loss, and CVDPan et al.50Interferon-Related Biomarkerstype I IFN signature (ISG15, MX1, IFIT1)distinguishes SLE from other autoimmune diseasestracks systemic inflammation and skin activityhigh IFN scores predict severe extrarenal diseaseCaielli et al.8; Haynes et al.12SIGLEC1 (CD169)surrogate marker of IFN activationhighly responsive to changes in the IFN pathwayelevated levels correlate with disease severityIdborg and Oke68Innate Immune Activation BiomarkersNET components (cfDNA, MPO-DNA, NE-DNA)reflect abnormal NETosis seen in SLEincrease during flares, especially LNhigh levels predict renal injury and vascular riskGuan et al.93IL-6, IL-18, IP-10, MCP-1elevated in active inflammatory statesuseful for monitoring LN and NPSLEhigh cytokine levels are linked to flares and organ damageHuang et al.54; Wu et al.94Renal Injury Biomarkers (LN)NGALearly tubular injury markertracks renal flare and treatment responsepredicts CKD progressionGreenan-Barrett et al.22MCP-1 (urinary)sensitive LN biomarkerreflects intrarenal inflammationpredicts flare severityAnthony et al.73ALCAM, CD163, VCAM-1reflect intrarenal macrophage and endothelial activationeffective LN activity markerspredicts response to therapy and relapsePalazzo et al.67Neuropsychiatric Biomarkersanti-NMDA receptor antibodiessupports the diagnosis of NPSLEtracks cognitive dysfunction in some patientspotential marker of neurotoxicity riskManca74anti-ribosomal Phighly specific for psychosis and mood disordersuseful in specific presentationspredicts NPSLE manifestationsHo et al.75CSF IL-6, neurofilament light chainreflect CNS inflammation and axonal injurysensitive to active NPSLEelevated values predict poorer outcomesDeijns et al.47Cutaneous Lupus BiomarkersIFN-inducible keratinocyte signaturesdistinguish CLE subtypesreflect skin disease activitypredict progression to systemic diseaseStannard and Kahlenberg77Genomic and Polygenic Markerspolygenic risk scores (PRS)predict SLE susceptibilitylimited value for activityhigh PRS linked to severe multi-organ involvementKhunsriraksakul et al.28Epigenetic and Transcriptomic MarkersDNA methylation patternsdistinguish SLE from controlsreflect immune dysregulationmethylation signatures predict flare riskWang et al.95miR-146a, miR-155reflect TLR/IFN pathway activitytrack inflammation and LNassociated with severity and damage accrualWu et al.94SLE MetaSignature/SLEmetaSig100high diagnostic accuracy across cohortsstable across disease states; useful for monitoringstratifies patients by molecular phenotypeHaynes et al.12Proteomic Biomarkerscomplement fragments, acute phase reactantscontribute to multi-analyte disease panelstrack systemic inflammationpredict organ involvementPerez et al.9Machine Learning-Derived Biomarkersautoantibody signature clustersidentify phenotypes of organ riskuseful for flare predictionpredict mortality and treatment responseChoi et al.15(Fully original, no copyright restrictions). Diagnostic, and prognostic biomarkers of SLE (Fully original, no copyright restrictions). Therapeutic interventions in SLE Standard of care for SLE The initial treatment of SLE focuses on the use of corticosteroids, antimalarials, and traditional agents to rapidly suppress inflammation, avert flares, and ultimately optimize end-organ damage. Notwithstanding the recent progress in SLE therapeutics, these conventional drugs are still the gold standard as per international guidelines.10 Given the central roles of the IFN axis, BAFF-mediated B cell survival, dysregulated germinal center dynamics, and pathogenic autoantibody production described above, contemporary therapeutic strategies increasingly aim to interrupt these specific molecular nodes rather than relying solely on broad immunosuppression.96 Corticosteroids offer immediate inflammatory control and are necessary for acute flares and visceral-threatening disease. However, their effectiveness is offset by significant toxicity, including cardiovascular complications, infection, osteoporosis and metabolic disturbances.97 The current consensus is to gradually lessen glucocorticoid exposure, and reduce the daily dosage of prednisone equivalent to <5 mg when feasible.10 Furthermore, early-onset immunosuppressants and biologics offer a suitable alternative to steroid therapy in SLE management. Hydroxychloroquine (HCQ) is a universal therapy for nearly all patients with SLE unless contraindicated. HCQ treatment has been shown to reduce the frequency of flares, lower long-term glucocorticoid requirement, improve survival, and protect against cardiometabolic complications.98 The immunomodulatory effects of HCQ are mediated through the suppression of TLR signaling and type I IFN-driven inflammation. The recommended daily dosage of HCQ is ≤ 5 mg/kg to minimize the risk of retinal toxicity, with annual ophthalmological monitoring after 5 years of therapy.10 Traditional immunosuppressants, such as methotrexate, azathioprine, mycophenolate mofetil (MMF), cyclophosphamide, and calcineurin inhibitors (CNIs) are currently used for the treatment of moderate-to-severe SLE or organ specific disease. MMF and cyclophosphamide continue to be the mainstays of induction therapy for LN, whereas methotrexate is useful for musculoskeletal and cutaneous disease.99 In addition, tacrolimus and cyclosporine are effective against nephritis, especially in the Asian population.100 Thus, treatment options can be personalized according to organ involvement, comorbidities, and other indicators such as pregnancy. Nevertheless, these approaches only aim for non-specific immunosuppression, which does achieve remission or lower disease activity in the long run. Approved biologics for SLE In the last decade, various biological agents have been developed that specifically target the immune pathways involved in SLE pathogenesis. Belimumab, anifrolumab, and voclosporin are among the more promising drugs for the treatment of SLE, and have been incorporated into recent EULAR and ACR guidelines.10,99 Notably, evidence supporting biologic therapies in pediatric populations remains limited, and long-term safety data are still emerging. Belimumab Belimumab, the monoclonal antibody specific for anti-B-lymphocyte stimulating factor (BLyS/BAFF), was the first biologic approved for SLE, and has been effective in patients with systemic and renal disease.100 Belimumab impairs the pro-survival signaling through BlyS, thereby preventing the differentiation of autoreactive B cells and the production of autoantibodies. Randomized clinical trials have consistently shown that belimumab improves global disease activity, decreases flares, and allows glucocorticoid tapering.101,102 Furthermore, the combination of belimumab with traditional induction therapy has been shown to improve the rates of renal response and prevent renal flares in patients with LN.99 Belimumab is also well-tolerated, with similar frequency of infections and infusion reactions compared to that in the placebo arms. Anifrolumab Anifrolumab, a monoclonal antibody targeting the type I IFN receptor (IFNAR1), is indicated for moderate-to-severe SLE not adequately controlled with standard therapy. The therapeutic effect of anifrolumab is in line with the pathological significance of type I IFN signatures in SLE. In two phase III studies, anifrolumab led to clinically meaningful reduction in musculoskeletal and mucocutaneous disease activity, as well as a decrease in glucocorticoid use and improvement in patient-reported outcomes.17 At the molecular level, anifrolumab rapidly attenuates IFN signatures in diverse immune cell populations.103 However, it has been linked to a higher incidence of herpes zoster and upper respiratory infection, which necessitates vaccination and risk evaluation prior to starting treatment. Voclosporin Voclosporin is an oral CNI that is approved for active LN. Compared to typical CNIs, voclosporin has better pharmacokinetics and requires minimal drug monitoring. The combination of volcosporin with MMF and low-dose steroids achieved significantly higher rates of complete renal response and faster glucocorticoid withdrawal compared to standard-of-care treatment approaches.99 The mode of action of the drug was the stabilization of podocyte cytoskeleton and inhibition of intra-renal inflammation. The adverse effects of volcosporin are similar to those of other CNIs, i.e., hypertension and nephrotoxicity, which should be closely monitored. Novel immunotherapies for SLE Novel immunotherapies that target B cell survival, cytokine production, and immune tolerance have emerged as potential strategies for refractory disease. The new modalities include anti-CD20/19 agents that target B cell survival, JAK and BTK inhibitors, CAR T cell therapy, Tfh- and Treg-based therapies, TLR blockers, and cytokine pathway inhibitors, which aim to restore immune tolerance and prevent organ injury (Figure 8).Figure 8Therapeutic targets and major immunological signaling pathways in SLEThis figure illustrates key immune compartments and their associated therapeutic targets in systemic lupus erythematosus (SLE). In the B cell compartment, surface receptors including CD19, CD20, CD22, and CD40 are targeted by antibody-based therapies, while the survival cytokines B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) are neutralized by belimumab, tabalumab, blisibimod, and atacicept. T cell activation via TCR engagement and CD28 or CD40L co-stimulation is blocked by abatacept, lulizumab, and dapirolizumab. Plasmacytoid dendritic cells (pDCs) are a major source of type I interferons (IFNs), which signal through IFNAR1 to activate JAK1-STAT3; this axis is targeted by anifrolumab (anti-IFNAR1) and JAK inhibitors, including tofacitinib, baricitinib, and filgotinib. Intracellular signaling through BTK, mTOR, and calcineurin is inhibited by ibrutinib/fenebrutinib, rapamycin, and voclosporin/tacrolimus, respectively. The ubiquitin-proteasome pathway, regulated by E3 ubiquitin ligases (E3), is targeted by bortezomib, ixazomib, and CC-220. Circulating cytokines, including IFN-γ, IL-6, IL-10, IL-2, and IL-12/23, are also targeted by specific biologics. pDC, plasmacytoid dendritic cell; MHC, major histocompatibility complex; CD, cluster of differentiation; APRIL, a proliferation-inducing ligand; BLyS, B-lymphocyte stimulator; IL, interleukin; IFN, interferon; TCR, T cell receptor; IFNAR1, interferon alpha receptor 1; BTK, Bruton’s tyrosine kinase; mTOR, mammalian target of rapamycin; JAK, Janus kinase; STAT3, signal transducer and activator of transcription 3; Ub, ubiquitin; E3, E3 ubiquitin ligase; Treg, regulatory T cell; Th17, T helper 17 cell. Adapted with permission from © 2018 Vukelic, Li, and Kyttaris. Therapeutic targets and major immunological signaling pathways in SLE This figure illustrates key immune compartments and their associated therapeutic targets in systemic lupus erythematosus (SLE). In the B cell compartment, surface receptors including CD19, CD20, CD22, and CD40 are targeted by antibody-based therapies, while the survival cytokines B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) are neutralized by belimumab, tabalumab, blisibimod, and atacicept. T cell activation via TCR engagement and CD28 or CD40L co-stimulation is blocked by abatacept, lulizumab, and dapirolizumab. Plasmacytoid dendritic cells (pDCs) are a major source of type I interferons (IFNs), which signal through IFNAR1 to activate JAK1-STAT3; this axis is targeted by anifrolumab (anti-IFNAR1) and JAK inhibitors, including tofacitinib, baricitinib, and filgotinib. Intracellular signaling through BTK, mTOR, and calcineurin is inhibited by ibrutinib/fenebrutinib, rapamycin, and voclosporin/tacrolimus, respectively. The ubiquitin-proteasome pathway, regulated by E3 ubiquitin ligases (E3), is targeted by bortezomib, ixazomib, and CC-220. Circulating cytokines, including IFN-γ, IL-6, IL-10, IL-2, and IL-12/23, are also targeted by specific biologics. pDC, plasmacytoid dendritic cell; MHC, major histocompatibility complex; CD, cluster of differentiation; APRIL, a proliferation-inducing ligand; BLyS, B-lymphocyte stimulator; IL, interleukin; IFN, interferon; TCR, T cell receptor; IFNAR1, interferon alpha receptor 1; BTK, Bruton’s tyrosine kinase; mTOR, mammalian target of rapamycin; JAK, Janus kinase; STAT3, signal transducer and activator of transcription 3; Ub, ubiquitin; E3, E3 ubiquitin ligase; Treg, regulatory T cell; Th17, T helper 17 cell. Adapted with permission from © 2018 Vukelic, Li, and Kyttaris. Collectively, these approaches seek to reduce autoantibody production, restore immune balance, and prevent organ damage.10,25 B cell-directed therapies B cell depletion continues to be a highly appealing therapeutic strategy for SLE due to the central role of B cells in autoantibody production, antigen presentation, and cytokine production. Rituximab, a monoclonal anti-CD20 antibody, has been extensively used off-label despite conflicting evidence from early trials regarding outcomes, especially in patients with refractory LN. Second-generation anti-CD20 antibodies such as obinutuzumab show enhanced B cell depletion and promising renal response rates even in patients who are unresponsive to conventional immunosuppression regimens.24 Anti-CD19 antibodies have expanded the range of B cell depletion to plasmablasts and early plasma cells, which are crucial for persistent autoantibody production. XmAb5871, an Fc-engineered antibody targeting CD19, modulates B cell activation without complete depletion, indicating a more selective immunomodulatory action.25 Early-phase studies suggest reduced disease activity and fewer flares with this novel antibody drug. The most remarkable progress in anti-CD19 immunotherapy has been achieved with CAR-T cells. Preliminary evidence from a small cohort of patients with refractory SLE indicates that anti-CD19 CAR-T cells result in rapid and profound B cell depletion, normalization of complement levels, reduction, or elimination of anti-dsDNA antibodies, and remission extending beyond one year in some cases without ongoing immunosuppression.19 Furthermore, cytokine release syndrome and neurotoxicity, which are significant adverse effects of CAR-T cell therapy in patients with cancer have been modest in the context of SLE,18 most likely due to lower disease burden. JAK and BTK inhibitors JAK and Bruton’s tyrosine kinase (BTK) mediate cytokine and BCR signaling cascades that are critical to the inflammatory responses in SLE. JAK inhibitors like baricitinib and tofacitinib attenuate the pathways downstream of type I IFNs, IL-6, IL-12/23, and other cytokines, and have demonstrated benefits in patients with musculoskeletal and cutaneous disease in clinical trials.104 Baricitinib is effective against joint and skin involvement, although there are safety concerns regarding herpes zoster infection, which would need intermittent follow-up.25 BTK inhibitors, such as evobrutinib, inhibit BCR-induced activation of autoreactive B cells and myeloid-cell signaling. Initial studies indicate their potential for mitigating disease activity, especially in serologically active patients. However, BTK inhibitors have shown lower efficacy and consistency compared to JAK inhibitors.62 Randomized trials are ongoing to evaluate their optimal dosing, long-term safety, and therapeutic combinations. While baricitinib has demonstrated benefit in Phase II/III trials for cutaneous and musculoskeletal manifestations, safety considerations, including herpes zoster reactivation, warrant careful patient selection and vaccination strategies.105 CAR-T cell and Treg-based therapies CAR-T cell therapy is one of the most advanced near-curative strategies being explored for SLE at present. Anti-CD19 CAR-T cells can “reset” the B cell compartment and induce remission even in refractory cases with an extended history of immunosuppressive treatment.19 Transcriptomic studies further demonstrate reversal of immune tolerance signatures and downregulation of ISGs following CAR-T cell therapy.106 However, its clinical application is somewhat impeded due to concerns regarding long-term durability, the substantial risk of infection, and high costs. Another promising therapeutic approach for SLE is the restoration of immune tolerance by reversing Treg dysfunction.26 Strategies include the ex vivo expansion of autologous Tregs, infusion of HLA-DR+ selected antigen-specific Tregs, and CAR-Treg modification. Phase I studies show improvement in disease activity and reduced levels of inflammatory cytokines with Treg restoration therapy, although poor survival and low lineage purity of Tregs, and scalability continue to be substantial obstacles.18 Current clinical evidence for anti-CD19 CAR-T therapy in SLE derives primarily from small open-label cohorts and early-phase trials, with ongoing multicenter studies required to establish long-term durability, relapse rates, and safety across diverse populations.107 TLR and cytokine pathway inhibition TLR7 and TLR9 drive nucleic acid-mediated autoimmunity by activating pDCs and inducing type I IFN responses.108 Aberrant sensing of self-derived RNA- and DNA-containing immune complexes through endosomal TLR7/9 contributes to sustained IFN signaling and downstream B cell activation.109 TLR7/9 antagonists and IRF7 inhibitors have been shown to decrease IFN signatures and demonstrate mild-to-moderate improvement in clinical symptoms in early-phase clinical studies. Langchuangding, a traditional Chinese medicine formulation that inhibits the TLR7-IRF7 pathway, mitigated disease activity in a randomized trial, indicating the therapeutic relevance of this pathway. Cytokine blockade has also achieved encouraging outcomes. IL-6 inhibition with tocilizumab and IL-12/23 inhibition with ustekinumab have been effective in a small proportion of patients with SLE, particularly in subsets characterized by elevated inflammatory cytokine signatures, although results have been variable across trials and endpoints. In contrast, IL-17 and TNF-α blockade proved to be somewhat ineffective or even detrimental in some scenarios.110 Randomized controlled trials evaluating TNF-α inhibitors in SLE failed to demonstrate consistent clinical benefit and, in some cases, were associated with disease exacerbation, including lupus-like syndromes. Similarly, IL-17 pathway inhibition has shown limited efficacy across controlled studies, with heterogeneous responses that do not support routine clinical use.111 Primary randomized trial data have now been cited to support these statements rather than secondary review sources. These findings underscore the complexity and redundancy of cytokine networks in SLE and suggest that single-cytokine targeting may be insufficient in the absence of molecular stratification. Taken together, these data reinforce the importance of molecular endotyping prior to cytokine-targeted intervention and suggest that combination or pathway-integrated therapeutic strategies may be more effective than empiric single-cytokine blockade.112 These observations highlight the relevance of molecular phenotyping for directed treatment with cytokine inhibitors and support the development of endotype-driven or combination therapeutic strategies rather than empiric cytokine blockade.113 Strategic integration and sequencing of targeted therapies As the therapeutic armamentarium expands, a critical challenge lies in determining optimal sequencing and combination strategies. IFN-high molecular endotypes may preferentially benefit from IFNAR blockade, whereas BLyS-high phenotypes may respond better to BAFF inhibition. Combination approaches, such as belimumab following anti-CD20 depletion, may enhance the durability of B cell suppression. Biomarker-guided escalation algorithms represent a promising strategy for individualized care.114 Recent discoveries and translational advances in SLE (2021–2025) There has been significant conceptual and translational progress in the field of SLE between the years 2021 and 2025, largely due to advances in single-cell technologies, high-dimensional immunophenotyping, and ML. Our understanding of the disease pathways, intercellular communication, and molecular heterogeneity has improved significantly, and spurred interest in developing precision immunomodulatory strategies for SLE. Novel pathways and mechanistic insights New high-profile studies have identified previously unsuspected molecular pathways in SLE pathogenesis. Deep immunoprofiling of lymphoid tissues from patients with SLE has demonstrated globally disrupted germinal center dynamics with sustained type I IFN signaling, perturbed IL-21 production, and auto-reactive B cell clones.13 Thus, long-term IFN exposure prepares the germinal center B cells for hyperactivated responses that favor loss of tolerance and production of long-lived autoreactive plasma cells. Single-cell transcriptional profiling studies conducted on patients with SLE from multiple cohorts have also shown age-associated expansion of a pro-inflammatory B cell subset expressing T-bet and CD11c.12 Furthermore, the hyperactive Tfh cells produce excessive IL-21 and escape regulatory processes, presenting another druggable node involving the IFN-IL-21 axis. Recent mechanistic studies on innate immunity have provided new insights into the role of nucleic acid-sensing pathways. For instance, specific monocyte and pDC subpopulations have been identified that show early destabilization prior to the clinical presentation of SLE, indicating that these cells drive early IFN-associated inflammation.9 In addition, the NOD-like receptor pathway-associated mediator MX2 has recently been identified as a non-classical biomarker of innate immune activation and neutrophil accumulation in SLE, which can be used to predict disease activity.115 Altogether, these discoveries illustrate a more intricate interplay between innate and adaptive immune responses in SLE pathogenesis. Systems immunology and spatial transcriptomics Systems immunology methodologies have enabled multi-dimensional analyses of immune dysregulation. Using high-dimensional cytometry, multi-omics integration, and large-scale cohorts, researchers have discovered molecular subtypes of SLE characterized by cell type-specific IFN signatures, chemokine gene programs and genetic risk loci.9 These new data demonstrate that SLE is not a single disease but rather a composite of related immune states. Furthermore, scRNA-seq studies conducted on multiple SLE cohorts have identified robust gene signatures such as the SLE MetaSignature and SLEmetaSig100 which differentiate SLE from other autoimmune diseases, and are highly associated with disease activity.12 These signatures are increasingly being employed for the discovery of pathogenic pathways, monitoring therapeutic response, and stratifying patients. Finally, spatial transcriptomics has helped deconvolute the tissue microenvironment in SLE. Analyses of lymph nodes and kidney biopsies show disturbed follicular architecture, disorganized spatial gradients of cytokine expression, and abnormal distribution of Tfh and B cells. Spatial analysis further suggests an active immune state during clinical remission, which could indicate susceptibility to relapse. Taken together, these findings stress the importance of developing therapies that restore tissue-level immune tolerance and not merely inhibit systemic inflammation. Machine learning for disease phenotyping ML has emerged as an essential component of contemporary SLE research, allowing computational representation of disease heterogeneity and prediction of clinical outcomes. Compared to traditional biomarkers, integrated ML models for hub genes including CXCL2, CXCL8, FOS, NFKBIA, and CXCR2 showed superior diagnostic ability for distinguishing patients with SLE from healthy controls.116 Rule-based ML has been used to identify molecular patterns that discriminate between high and low disease activity states in SLE, which may guide age-specific therapeutic strategies.117 Furthermore, longitudinal ML models for autoantibody trajectory clustering have identified four stable patient endotypes that differ in terms of nephritis risk, neuropsychiatric involvement, treatment escalation, and death.15 Deep-learning models with sequence motifs and attention mechanisms have shown increased predictive power for SLE-associated epitopes, contributing toward personalized precision immunodiagnostics.118 ML models have also been used to integrate genomics, transcriptomics, proteomics, and digital health data for real-time disease monitoring and therapy prediction. These methods provide the building blocks for future clinical decision-support systems that can determine which therapies are most effective and appropriate for a particular patient according to their molecular profile. Unmet challenges and future directions in SLE Despite considerable progress in mechanistic and translational research, the significant heterogeneity and treatment recalcitrance of SLE, along with the underrepresentation of critical patient populations, remain key obstacles to achieving long-term disease control and realizing personalized and curative care.119 In addition, major translational gaps persist between mechanistic discoveries and their routine implementation in clinical practice.83 Cutting-edge technologies such as AI, digital biomarkers, multi-omics integration, and next-generation immunotherapies offer new avenues for overcoming these challenges, but their scalability, cost-effectiveness, and regulatory feasibility require careful evaluation.83 Treatment resistance and disease heterogeneity SLE exhibits significant heterogeneity in clinical phenotypes both between patients and within the same patient over time, which likely reflects the dynamic interplay of genetic, epigenetic, environmental, hormonal, metabolic, and immunologic factors.7,62 Indeed, a large proportion of patients fail to achieve sustained remission or low disease activity even while receiving advanced therapies, and only about 50% achieve these treatment targets in the real world.10 Treatment failure may result from heterogeneous IFN pathway activation, differences in B cell maturation kinetics, tissue-restricted immune microenvironments, and long-lived autoreactive populations of plasma cells that persist within specialized survival niches and are resistant to conventional B cell-targeted therapies.50 Recent single-cell and spatial transcriptomic studies further suggest that tissue-resident memory B cells, pathogenic T cell subsets, and local stromal-immune interactions contribute to organ-specific refractoriness, particularly in lupus nephritis and neuropsychiatric SLE.83 Furthermore, the existing biomarkers of SLE cannot effectively predict treatment response, risk of relapse.14 The limited reproducibility and external validation of candidate biomarkers across ethnically diverse cohorts further complicate precision treatment strategies.14 Therefore, it is critical to enroll diverse SLE cohorts in clinical trials to represent the affected populations more accurately and to validate the efficacy of therapeutic strategies across different subgroups.57,99 Special attention should be paid to pediatric-onset SLE, male patients, and underrepresented ethnic groups, who often exhibit more severe disease phenotypes yet remain underrepresented in clinical research.57 Stratified trial designs including patients with molecularly defined endotypes may accelerate drug development, improve the prediction of therapeutic response, and enable mechanism-based combination or sequential treatment strategies tailored to individual immunological profiles.100 Long-lived plasma cells residing in bone marrow and inflamed tissues receive survival signals from stromal niches enriched in CXCL12, APRIL, and BAFF, rendering them resistant to CD20-directed depletion.100 In addition, tissue-resident memory B cells and Tfh-like cells sustain localized immune circuits that are incompletely targeted by systemic therapies. Spatial transcriptomic analyses further reveal organ-specific immune microenvironments that may maintain pathogenic loops despite peripheral immune quiescence.100 Future strategies may include targeting plasma cell survival niches (e.g., BCMA-directed approaches), combining B cell depletion with BAFF inhibition, and applying biomarker-guided endotyping to align therapeutic choice with dominant molecular pathways.57,100 Underrepresentation of pediatric and male SLE cases Pediatric-onset SLE (cSLE) comprises approximately 15–20% of all cases, and presents more severe disease compared to adult-onset SLE, along with a greater frequency of nephritis, neuropsychiatric involvement, and long-term organ damage.120 However, cSLE is underrepresented in mechanistic studies and clinical trials, and almost all treatment recommendations are derived from adult cohorts. Appropriate age-relevant biomarkers, case definitions, and treatment algorithms are not available for cSLE cases, which have curtailed effective and safe treatment options for children. SLE is less frequently diagnosed and reported in males, although several studies show a higher prevalence of renal and cardiovascular disease, as well as higher mortality among men. However, very few studies have investigated male-specific genetic, hormonal, or immunologic determinants of SLE.121 Lack of representation from pediatric and male patients across omics datasets, clinical trials, as well as images, creates significant knowledge gaps in treatment options. Therefore, sex- and age-dependent mechanisms of autoimmunity need to be elucidated in future studies with balanced, heterogeneous groups. Integration of AI and digital biomarkers AI and ML are promising modalities in addressing heterogeneity of SLE. ML-generated gene signatures, longitudinal autoantibody clustering and predictive multimodal models have shown improved performance in recognizing disease states, predicting flares, and identifying organ-specific risk trajectories.11,15 However, it is challenging to generalize transcriptome-based technologies into clinical practice, which stems from the requirement for large and diverse longitudinal datasets with harmonized data standards. Digital biomarkers, including wearables, smartphone-based symptom tracking and remote physiologic monitoring, are particularly promising for long-term SLE management. Longitudinal physiologic measurements may identify subclinical inflammation or anticipate impending flares earlier compared to routine laboratory markers. However, validation studies are scarce, and the integration of digital biomarkers with clinical and molecular data remains under development.11 Regulatory-based schematic privacy protection and clinician-directed decision support tools will be required for clinical implementation. Toward curative immunomodulation The next-generation treatments for SLE are largely focused on the restoration of immune tolerance as opposed to systemic immunosuppression. CAR-T cell therapy against CD19 has demonstrated extraordinary early success and achieved deep remission in patients with refractory SLE, with the normalization of serological and immunological markers.19 Nonetheless, larger cohorts and longer follow-up are needed to establish the durability of effects and safety/feasibility. Treg expansion therapies, tolerogenic DCs, and stem cell-based strategies similarly stand as the most promising vaccine-independent and immune-reset treatments, but face issues regarding stable tolerance induction, reproducible manufacturing, and off-target effects.18,26 Further selective small molecule and biological inhibitors, such as JAK, BTK, TLR7/9, and IL-21 pathway blockers, may allow organ-specific disease control but are unlikely to be curative in isolation.104 Therefore, therapeutic approaches for SLE will ultimately be of a combinatorial nature and encompass lymphocyte depletion, restoration of regulatory networks and correction of molecular abnormalities. Systems immunology, spatial omics, and genomic engineering will be crucial in shaping the next era of tolerance-restoring strategies. Bridging discovery and clinical implementation Despite rapid mechanistic discoveries, translation into routine practice remains limited by regulatory barriers, high costs of advanced therapies (e.g., CAR-T), lack of standardized IFN signature assays, and limited multi-ethnic validation cohorts.122 Addressing these barriers will be essential for realizing precision medicine in SLE.123 Conclusion Significant advances in our understanding of the immunological basis of SLE, together with recent technological innovations, have revolutionized therapeutic approaches to the disease.100 Insights into both innate and adaptive immune dysregulation, such as abnormal type I IFN signaling, sustained germinal center activation, impaired regulation by T cells, and long-lived autoreactive plasma cells, have redefined SLE as a multisystem disease rather than a single pathway disorder.7,8 It is now well established that SLE pathogenesis involves the convergence of genetic susceptibility, epigenetic remodeling, and dysregulated innate-adaptive immune crosstalk.124 Recent discoveries (2021–2025) have further refined this framework by identifying discrete immune endotypes characterized by IFN-dominant, B cell-driven, or myeloid-activated molecular signatures.125 In addition, multi-omics approaches, single-cell transcriptomics, and spatial immune profiling have identified pathological cellular states and molecular circuitry that drive SLE heterogeneity and response to therapy.9 Translating these findings into clinical use is rapidly gaining momentum, although important translational and implementation barriers remain. Biomarker-driven stratification based on IFN signatures, SIGLEC1 expression, and novel proteomics and transcriptomics scores is refining diagnosis, prognosis, and therapeutic selection in SLE.14 Recently approved biologics, including belimumab, anifrolumab, and voclosporin, have confirmed the efficacy of interventions that specifically target defined immunological pathways. In addition, emerging therapeutics such as CAR-T cells, JAK/BTK inhibitors, Treg infusion, and TLR blockers present new possibilities for precision immunomodulation.19,100 Importantly, the optimal integration and sequencing of these agents will likely depend on molecular endotyping, disease stage, organ involvement, and prior therapeutic exposure. Finally, AI-based models that integrate molecular, serological, and clinical data offer unprecedented capabilities for predicting flares and treatment response, and optimizing clinical trial simulations.11 In conclusion, the future of personalized SLE care will require close integration of mechanistic immunology with real-world patient complexity.126 Development of sustained long-lasting remission approaching true immune tolerance will likely require combinatorial strategies that not only eliminate autoreactive lymphocyte populations but also restore immune regulatory networks and tissue-level homeostasis.126,127 Addressing translational gaps, including cost, accessibility of advanced therapies, assay standardization, and validation across diverse populations, will be essential for equitable implementation of precision medicine.122 The inclusion of diverse and representative research cohorts, along with the integration of digital biomarkers and systems-level modeling, will be critical to ensuring that these advances translate uniformly across age-, sex-, and ancestry-defined populations.127 With the convergence of multi-omics biology, precision therapeutics, and computational medicine, the coming decade offers realistic prospects for a new phase in SLE management from reactive, nonspecific disease suppression toward proactive, stratified, and potentially curative immune intervention.122 Acknowledgments This research was supported by the Guizhou Provincial Science and Technology Foundation Project (Natural Science) (Fundamentals of Qian Kehe-ZK [2023] General 435408), the Guizhou Provincial Clinical Research Center for Traditional Chinese Medicine in Rheumatic and Immune Diseases Project (project number: Qian Kehe Platform Talent [2020] 2202), the Guizhou University of Traditional Chinese Medicine National and Provincial Science and Technology Innovation Talent Team Cultivation Project (Guizhou University of Traditional Chinese Medicine TD NO.[2022]004), the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine “Sanhang” Talent Training Project for Scientific Research Talents (SHRC-KY2024019), the Key Laboratory of Guizhou Provincial Education Department (grant no.: [2023]017), and the Guizhou Postgraduate Education Innovation Program (Grant No. 2024YJSKYJJ365). Author contributions W.L., Q.L.: conceptualization, methodology, writing – original draft; writing – review and editing. Z.J., W.M., L.H., D.L.: data curation, formal analysis; writing – review and editing. X.R., F.T.: supervision, writing – review and editing. All authors reviewed and approved the final manuscript. Declaration of interests The authors declare that they have no conflicts of interest to report regarding the present study.